Back to News
Jan 9, 2026 12:40 PM

Mesoblast Stock Rises On Strong Year‑Over‑Year Growth In Ryoncil Sales

Mesoblast Ltd (NASDAQ:MESO) shares are trading higher on Friday after the company reported strong year‑over‑year growth in December quarter sales of its flagship therapy, Ryoncil.

Mesoblast stock is approaching key resistance levels. Why are MESO shares at highs?

What Happened: Mesoblast posted $35.1 million in gross revenue from Ryoncil (remestemcel‑L‑rknd) for the quarter ending Dec. 31, 2025, representing a 60% jump from the previous quarter ending Sept. 30.

Ryoncil is the first mesenchymal stromal cell therapy ever approved by the FDA, and it remains the only FDA‑approved treatment for children under 12 with steroid‑refractory acute graft‑versus‑host disease. The therapy is now moving into a crucial trial as a second‑line option for adults with the same condition, a market roughly three times larger than the pediatric segment.

The ...